株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

喘息治療薬の世界市場 - 規模、シェア、見通し、および機会分析

Asthma Therapeutics Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

発行 Coherent Market Insights 商品コード 883788
出版日 ページ情報 英文 157 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=111.24円で換算しております。
Back to Top
喘息治療薬の世界市場 - 規模、シェア、見通し、および機会分析 Asthma Therapeutics Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026
出版日: 2019年06月12日 ページ情報: 英文 157 Pages
概要

当レポートでは世界の喘息治療薬市場について調査しており、市場機会や成長および阻害要因、薬剤クラス・投与経路・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 研究の目的および仮定

  • 研究目的
  • 仮定
  • 略語

第2章 市場の概要

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 薬剤クラス別
    • 投与経路別
    • 流通チャネル別
    • 地域別
  • COM (Coherent Opportunity Map)

第3章 市場力学、規制および動向分析

  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会
  • 影響分析
  • 市場動向
  • 主な開発
  • 技術の進歩
  • 疫学
  • 製品リコール
  • 政府の取り組み
  • 歴史的概要
  • 合併と買収
  • 規制および償還シナリオ
  • ポーターのファイブフォース分析
  • PEST分析

第4章 世界の喘息治療薬市場:薬剤クラス別

  • イントロダクション
  • コルチコステロイド
  • ベータ2作動薬(長時間作用型および短時間作用型)
  • ロイコトリエン阻害剤
  • 長時間作用型ムスカリン拮抗薬(LAMA)
  • インターロイキン拮抗薬
  • 抗免疫グロブリンE(IgE)剤
  • コンビネーション製品(ベータ2作動薬/コルチコステロイド、ベータ2作動薬/ムスカリン拮抗薬/コルチコステロイドおよびその他を含む)
  • その他

第5章 世界の喘息治療薬市場:投与経路別

  • 経口
  • 吸入
  • 注入

第6章 世界の喘息治療薬市場:流通チャネル別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 世界の喘息治療薬市場:地域別

  • イントロダクション
  • 北米
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • フランス
    • スペイン
    • ロシア
    • その他の欧州
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • ASEAN
    • オーストラリア
    • 韓国
    • その他のアジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
    • その他のラテンアメリカ
  • アフリカ
    • 北アフリカ
    • 中央アフリカ
    • 南アフリカ
  • 中東
    • GCC諸国
    • イスラエル
    • その他の中東

第8章 競合情勢

  • ヒートマップ解析
  • 企業プロファイル
    • GlaxoSmithKline Plc.
    • Philips Healthcare
    • AstraZeneca Plc.
    • Teva Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim GmbH
    • Sanofi- Aventis SA
    • CareFusion Corporation
    • Sunovion Pharmaceutical Ltd.
    • Merck & Co. Inc.
    • Roche Diagnostics
  • アナリストの意見

第9章 セクション

  • 参考文献
  • 調査方法
  • 当社と販売について
目次

Asthma is a long-term inflammatory disease that causes inflammation and narrowing of the airways in the lung. It is characterized by various symptoms such as swelling or inflammation in the airways linings, coughing, shortness of breath, and tightness of chest. Asthma is classified into many different types including allergic asthma, non-allergic asthma, adult onset asthma, exercised induced asthma (that occurs with physical exertion), nocturnal asthma, and occupational asthma. Nocturnal is also known as the nighttime asthma. It is very serious type of asthma therefore, it needs a proper diagnosis and treatment.

Market Dynamics:

Increasing launches of nebulizer by key players is expected to propel global asthma therapeutics market growth. For instance, in October 2018, Koninklijke Philips N.V. announced launch of its new mesh nebulizer, InnoSpire Go, in North America. This is used for the treatment of respiratory diseases including asthma. It is portable, hand-held nebulizer system, which is short time treatment. It delivers the medicine in just four minutes. InnoSpire Go designed for both adults and children.

However, product recall is major restraining factor for asthma therapeutics market growth, which is expected to hamper the market growth. For instance, in August 2018, Camber Pharmaceuticals were issued product recall alert from U.S. Food and Drug Administration for its Montelukast Sodium Tablets. These tablets are recalled because Montelukast Sodium Tablet bottles contain wrong medicine (Losartan Potassium Tablet).

Key features of the study:

  • This report provides in-depth analysis of the global asthma therapeutics market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global asthma therapeutics market based on the following parameters-company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
    • Key players covered as a part of this study include, GlaxoSmithKline Plc., Philips Healthcare, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc. Merck & Co., Inc., and Roche Diagnostics.
    • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
    • The global asthma therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for global asthma therapeutics market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Asthma Therapeutics Market, By Drug Class:
    • Corticosteroids
    • Beta2-Agonists (Long-Acting and Short-Acting)
    • Leukotriene Inhibitors
    • Long-Acting Muscarinic Antagonists (LAMA)
    • Interleukin Antagonists
    • Anti-Immunoglobulin E (IgE) Agents
    • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
    • Others
  • Global Asthma Therapeutics By Route of Administration:
    • Oral
    • Inhalation
    • Injection
  • Global Asthma Therapeutics market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Asthma Therapeutics market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
    • By Drug Class
  • Corticosteroids
  • Beta2-Agonists (Long-Acting and Short-Acting)
  • Leukotriene Inhibitors
  • Long-Acting Muscarinic Antagonists (LAMA)
  • Interleukin Antagonists
  • Anti-Immunoglobulin E (IgE) Agents
  • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
  • Others
    • By Route of Administration:
  • Oral
  • Intravenous
  • Subcutaneous
    • By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Europe
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
    • By Drug Class
  • Corticosteroids
  • Beta2-Agonists (Long-Acting and Short-Acting)
  • Leukotriene Inhibitors
  • Long-Acting Muscarinic Antagonists (LAMA)
  • Interleukin Antagonists
  • Anti-Immunoglobulin E (IgE) Agents
  • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
  • Others
    • By Route of Administration:
  • Oral
  • Intravenous
  • Subcutaneous
    • By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Asia Pacific
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
    • By Drug Class
  • Corticosteroids
  • Beta2-Agonists (Long-Acting and Short-Acting)
  • Leukotriene Inhibitors
  • Long-Acting Muscarinic Antagonists (LAMA)
  • Interleukin Antagonists
  • Anti-Immunoglobulin E (IgE) Agents
  • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
  • Others
    • By Route of Administration:
  • Oral
  • Intravenous
  • Subcutaneous
    • By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
    • By Drug Class
  • Corticosteroids
  • Beta2-Agonists (Long-Acting and Short-Acting)
  • Leukotriene Inhibitors
  • Long-Acting Muscarinic Antagonists (LAMA)
  • Interleukin Antagonists
  • Anti-Immunoglobulin E (IgE) Agents
  • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
  • Others
    • By Route of Administration:
  • Oral
  • Intravenous
  • Subcutaneous
    • By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
    • By Drug Class
  • Corticosteroids
  • Beta2-Agonists (Long-Acting and Short-Acting)
  • Leukotriene Inhibitors
  • Long-Acting Muscarinic Antagonists (LAMA)
  • Interleukin Antagonists
  • Anti-Immunoglobulin E (IgE) Agents
  • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
  • Others
    • By Route of Administration:
  • Oral
  • Intravenous
  • Subcutaneous
    • By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
    • By Drug Class
  • Corticosteroids
  • Beta2-Agonists (Long-Acting and Short-Acting)
  • Leukotriene Inhibitors
  • Long-Acting Muscarinic Antagonists (LAMA)
  • Interleukin Antagonists
  • Anti-Immunoglobulin E (IgE) Agents
  • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
  • Others
    • By Route of Administration:
  • Oral
  • Intravenous
  • Subcutaneous
    • By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Company Profiles
  • GlaxoSmithKline Plc.,*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Philips Healthcare
  • AstraZeneca Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim GmbH
  • Sanofi-Aventis SA
  • CareFusion Corporation
  • Sunovion Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Roche Diagnostics.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Technology Advancements
  • Epidemiology
  • Product Recalls
  • Government Initiatives
  • Historical Overview
  • Merger and Acquisition
  • Regulatory and Reimbursement Scenario
  • PORTER'S Five Forces
  • PEST Analysis

4. Global Asthma Therapeutics Market, By Drug Class, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Corticosteroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Beta2-Agonists (Long-Acting and Short-Acting)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Leukotriene Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million
  • Long-Acting Muscarinic Antagonists (LAMA)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million
  • Interleukin Antagonists
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million
  • Anti-Immunoglobulin E (IgE) Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million
  • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million

5. Global Asthma Therapeutics Market, By Route of Administration, 2018 - 2026, (US$ Million)

  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million
  • Inhalation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million
  • Injection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million

6. Global Asthma Therapeutics Market, By Distribution Chanel, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospitals Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

7. Global Asthma Therapeutics Market, By Region, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast By Country, 2016 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channels, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2026, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channels, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
  • GCC Countries
  • Israel
  • Rest of Middle East

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
  • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Philips Healthcare
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • AstraZeneca Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Boehringer Ingelheim GmbH
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Sanofi- Aventis SA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • CareFusion Corporation
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Sunovion Pharmaceutical Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Merck & Co. Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Roche Diagnostics
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top